Encysive Pharmaceuticals Inc - Amended Statement of Beneficial Ownership (SC 13D/A)
April 16 2008 - 4:50PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)
ENCYSIVE PHARMACEUTICALS INC.
|
(Name of Issuer)
|
Common Stock, par value $0.005 per share
|
(Title of class of securities)
|
29256X107
|
(CUSIP number)
|
Margaret M. Foran, Esq.
Pfizer Inc.
235 East 42nd Street
New York, NY 10017
Phone (212) 573-2323
with a copy to:
Raymond O. Gietz, Esq.
Weil, Gotshal & Manges LLP
767 Fifth Avenue
New York, New York 10153
|
(Name, address and telephone number of person authorized
to receive notices and communications)
|
April 14, 2008
|
(Date of event which requires filing of this
statement)
|
If the
filing person has previously filed a statement on Schedule 13G to report the
acquisition which is the subject of this Schedule 13D, and is filing this schedule
because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box
o
.
CUSIP No.
226406106
|
13D
|
Page 2
|
1.
|
NAME OF REPORTING PERSON: PFIZER INC.
|
2.
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A
GROUP:
|
(a)
x
(b) [_]
|
3.
|
SEC USE ONLY
|
4.
|
SOURCE OF FUNDS:
|
WC
|
5.
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEM
2(d) OR 2(e):
o
|
6.
|
CITIZENSHIP OR PLACE OF ORGANIZATION:
|
Delaware
|
NUMBER
OF SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7.
|
SOLE VOTING POWER:
|
69,076,466
(See Item 5)
|
|
8.
|
SHARED VOTING POWER:
|
-0-
|
9.
|
SOLE DISPOSITIVE POWER:
|
69,076,466 (See Item 5)
|
10.
|
SHARED DISPOSITIVE POWER:
|
-0-
|
11.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON:
|
69,076,466 (See Item 5)
|
|
12.
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES:
|
|
o
|
13.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW
(11):
|
85.33%
(See Item 5)
|
|
14.
|
TYPE OF REPORTING PERSON:
|
CO
|
|
|
|
|
|
|
|
CUSIP No.
226406106
|
13D
|
Page 3
|
1.
|
NAME OF REPORTING PERSON: EXPLORER ACQUISITION
CORP.
|
2.
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A
GROUP:
|
(a)
x
(b) [_]
|
3.
|
SEC USE ONLY
|
4.
|
SOURCE OF FUNDS:
|
AF
|
5.
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEM
2(d) OR 2(e):
o
|
6.
|
CITIZENSHIP OR PLACE OF ORGANIZATION:
|
DELAWARE
|
NUMBER
OF SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7.
|
SOLE VOTING POWER:
|
69,076,466 (See Item 5)
|
|
8.
|
SHARED VOTING POWER:
|
-0-
|
9.
|
SOLE DISPOSITIVE POWER:
|
69,076,466 (See Item 5)
|
10.
|
SHARED DISPOSITIVE POWER:
|
-0-
|
11.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON:
|
69,076,466 (See Item 5)
|
|
12.
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES:
|
|
o
|
13.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW
(11):
|
85.33%
(See Item 5)
|
|
14.
|
TYPE OF REPORTING PERSON:
|
CO
|
|
|
|
|
|
|
|
This
Amendment No. 1 (the “Amendment”) amends the Statement on Schedule 13D
filed on April 11, 2008 (the “Original Schedule”) by the Reporting Persons
(the Original Schedule as amended by this Amendment is referred to as the
“Schedule 13D”) and is filed by Pfizer Inc. (“Pfizer”), and its
wholly-owned subsidiary, Explorer Acquisition Corp. (“Explorer” or the
“Purchaser”), and relates to the common stock, including the associated
preferred stock purchase rights (“Common Stock”), $0.005 par value per
share, of Encysive Pharmaceuticals Inc., a Delaware corporation (“Encysive”
or the “Company”). Unless otherwise indicated, all capitalized terms used
herein have the meaning ascribed to them in the Original Schedule.
Item 5.
|
Interests in the Securities of the
Purchaser.
|
(a) and (b) As a result of purchases of Shares pursuant
to the Offer, on April 15, 2008, Pfizer and Explorer beneficially own an aggregate
69,076,466 shares (the “Shares”) of Common Stock, representing 85.33% of
the outstanding shares of Common Stock (based upon 80,955,060 Shares issued and
outstanding as of April 14, 2008, as reported to the Reporting Persons by the transfer
agent for the Shares). Pfizer and Explorer each have sole voting and dispositive power
of all the Shares by virtue of the fact that Explorer, the record holder of the Shares,
is a wholly-owned subsidiary of Pfizer.
(c) Since the filing of the Original Schedule and
through the expiration of the subsequent offering period at 5:00 p.m., New York City
time, on April 14, 2008, Explorer purchased the following number of Shares on the
following dates at the offer price of $2.35 per Share:
Date
:
|
Number of
Shares
:
|
|
April 11, 2008
|
155,499
|
|
April 14, 2008
|
1,232,412
|
|
(d) Except as set forth in this Amendment, none
of the Reporting Parties has the right to receive or the power to direct the receipt of
dividends from, or the proceeds of the sale of, securities covered by the Schedule
13D.
4
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated:
April 16, 2008
PFIZER INC.
|
Name:
|
David Reid
|
|
Title:
|
Assistant Secretary
|
EXPLORER ACQUISITION CORP.
|
By:
|
/s/ Lawrence R.
Milller
|
|
Name:
|
Lawrence R. Miller
|
|
Title:
|
Vice President
|
Encysive Pharmaceuticals (MM) (NASDAQ:ENCY)
Historical Stock Chart
From Jul 2024 to Aug 2024
Encysive Pharmaceuticals (MM) (NASDAQ:ENCY)
Historical Stock Chart
From Aug 2023 to Aug 2024